Emergent BioSolutions Inc. (EBS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Emergent BioSolutions Inc. (EBS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 46/100 — a percentile rank of Emergent BioSolutions Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $326.6M |
| P / S | 0.4× |
| EV / EBITDA | 3.3× |
| Gross margin | 55.9% |
| Operating margin | -8.6% |
| Net margin | -23.0% |
| Return on equity | -51.8% |
| ROIC | -10.2% |
| Revenue growth | -9.6% |
| Debt / equity | 1.7× |
| Dividend yield | 0.0% |
Is Emergent BioSolutions Inc. overvalued? P/S looks fair vs its 5-year range; EV/EBITDA looks undervalued vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from Emergent BioSolutions Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact